AngioDynamics Stock Is Falling Thursday: What's Going On?
ANGO stock drops 21% as AngioDynamics reports Q1 results, names Eric Honroth as new CEO, and reaffirms FY27 guidance.
Stocks · News reference
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings
U.S. stocks fell Thursday as Nasdaq slid 150+ points; energy rallied, healthcare dropped. PepsiCo beat estimates but cut FY26 outlook; oil jumped 5%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AngioDynamics shares are trading lower after the company reported Q1 financial results. The company reported a year-over-year decrease in its AngioVac sales.
AngioDynamics Q1 2027 Earnings Call: Complete Transcript
AngioDynamics (NASDAQ:ANGO) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you by Benzinga
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
A Dutch patent court ruled that Merck's Keytruda subcutaneous formulation infringes Halozyme's MDASE patent, ordering Merck to cease manufacturing and sales across eight European markets. The ruling does not affect Keytruda's intravenous version. This marks another legal victory for Halozyme against Merck, though the company clarified that its separate ENHANZE technology and licensing business remain unaffected.
Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis
Argenx announced Phase 2 success for FB102 in celiac disease while halting its Phase 3 UNITY study in Sjögren's disease for futility.
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures fell, with Dow futures down 450 points. Argenx sank 8.7% after a Sjögren’s trial was halted for futility; others also slid.